Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 10/20 | 0.59 |
| ▸ | IKZF2 | Q9UKS7 | 8/20 | 0.50 |
| ▸ | WIZ | O95785 | 1/20 | 0.50 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.49 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL31204436 | 0.99 | CRBN (0.58) | CRBNIKZF2WIZCSNK1A1IKZF1 | |
| Hydrochloric Acid SCHEMBL31726759 | 0.99 | CRBN (0.58) | CRBNIKZF2WIZCSNK1A1IKZF1 | |
| SCHEMBL31205644 | 0.94 | CRBN (0.57) | CRBNIKZF2WIZCSNK1A1IKZF1 | |
| SCHEMBL30984957 | 0.94 | CRBN (0.57) | CRBNIKZF2WIZCSNK1A1IKZF1 | |
| SCHEMBL27302693 | 0.92 | IKZF2 (0.55) | CRBNIKZF2WIZCSNK1A1 | |
| Hydrochloric Acid SCHEMBL31727422 | 0.91 | CRBN (0.58) | CRBN | |
| SCHEMBL24571921 | 0.91 | CRBN (0.60) | CRBNIKZF2WIZCSNK1A1IKZF1 | |
| SCHEMBL31728131 | 0.91 | CRBN (0.60) | CRBNIKZF2WIZCSNK1A1 | |
| SCHEMBL30702623 | 0.91 | CRBN (0.60) | CRBNIKZF2WIZCSNK1A1 | |
| SCHEMBL31027850 | 0.91 | CRBN (0.60) | CRBNIKZF2WIZCSNK1A1IKZF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260014260-A1 | MDM2 DEGRADER | NEWAVE PHARMACEUTICAL INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-20250367193-A1 | BIFUNCTIONAL COMPOUNDS CONTAINING SUBSTITUTED PYRIMIDINE DERIVATIVES FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEASOME PATHWAY | NIKANG THERAPEUTICS INC (DE) | 2025-12-04 | — | — | US | disclosed |
| EP-4543861-A1 | BIFUNCTIONAL COMPOUNDS CONTAINING PYRIMIDINE DERIVATIVES FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEASOME PATHWAY | Nikang Therapeutics, Inc. (US) | 2025-04-30 | — | — | EP | disclosed |
| CN-119630644-A | Bifunctional compounds containing pyrimidine derivatives for degradation of cyclin-dependent kinase 2 via the ubiquitin proteasome pathway | 霖康疗法公司 | 2025-03-14 | — | — | CN | disclosed |
| CN-119630651-A | Bifunctional compounds containing substituted pyrimidine derivatives for degradation of cyclin-dependent kinase 2 via the ubiquitin proteasome pathway | 霖康疗法公司 | 2025-03-14 | — | — | CN | disclosed |
| WO-2024097989-A1 | RET-LDD PROTEIN DEGRADERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-05-10 | — | — | WO | disclosed |
| WO-2023250029-A1 | BIFUNCTIONAL COMPOUNDS CONTAINING SUBSTITUTED PYRIMIDINE DERIVATIVES FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEASOME PATHWAY | NIKANG THERAPEUTICS, INC. (US) | 2023-12-28 | — | — | WO | disclosed |
| WO-2023249970-A1 | BIFUNCTIONAL COMPOUNDS CONTAINING PYRIMIDINE DERIVATIVES FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEASOME PATHWAY | NIKANG THERAPEUTICS, INC. (US) | 2023-12-28 | — | — | WO | disclosed |
| WO-2023230059-A1 | MDM2 DEGRADER | NEWAVE PHARMACEUTICAL INC. (US) | 2023-11-30 | — | — | WO | disclosed |
| US-20220169643-A1 | ESTROGEN RECEPTOR DEGRADING PROTACS | ASTRAZENECA UK LIMITED (GB) | 2022-06-02 | — | — | US | disclosed |
| EP-3947376-A1 | ESTROGEN RECEPTOR DEGRADING PROTACS | Astrazeneca AB (SE) | 2022-02-09 | — | — | EP | disclosed |
| WO-2020201080-A1 | ESTROGEN RECEPTOR DEGRADING PROTACS | ASTRAZENECA AB (SE) | 2020-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014260-A1 | MDM2 DEGRADER | MDM2, TP53, ADRM1 | CRBN 29/4885IKZF2 3360/4885WIZ 4029/4885 |
| US-20220169643-A1 | ESTROGEN RECEPTOR DEGRADING PROTACS | ESR1, GPER1, ESRRG | CRBN 576/4885IKZF2 1887/4885WIZ 1893/4885 |
| US-20250367193-A1 | BIFUNCTIONAL COMPOUNDS CONTAINING SUBSTITUTED PYRIMIDINE DERIVATIVES FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEASOME PATHWAY | CDK2, SKP2, CCNK | CRBN 402/4885IKZF2 2343/4885WIZ 3185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.